Accentia Biopharmaceuticals Company Profile - Aug 23, 2011 by WrightReports

VIEWS: 55 PAGES: 11

More Info
									Company Fundamentals\Company Profile

   A Wright Investors' Service Research Report:

   Accentia Biopharmaceuticals, Inc.
                                                                                        440 Wheelers Farms Road
                                                                                        Milford, CT 06461 U.S.A.


  COMPANY PROFILE
  Figures in U.S. Dollars

                                 Wright Quality Rating:LCNN                                  Key Data

   Accentia Biopharmaceuticals, Inc. (Accentia) is a biotechnology company that is           Ticker:
   developing Revimmune as a system of care for the treatment of autoimmune                  ABPI
   diseases. Through the Company's, subsidiary, Biovest International, Inc., it is
   developing BiovaxID as a therapeutic cancer vaccine for treatment of follicular non-      2010 Sales:
   Hodgkin's lymphoma (FL) and mantle cell lymphoma (MCL). Through its wholly owned
                                                                                             10,455,513
   subsidiary, Analytica International, Inc., it conducts a health economics research
   and consulting business, which it market to the pharmaceutical and biotechnology
   industries, using its operating cash flow to support its corporate administration and     Major Industry:
   product development activities. Revimmuneis developed as a treatment for various          Drugs, Cosmetics & Health
   autoimmune diseases. As a system of care, Revimmune consists of administering             Care
   high, pulsed doses of cyclophosphamide, over a four-day interval as part of an
   integrated risk management system, including a panel of preventive tests, monitoring      Sub Industry:
   and medications.                                                                          Ethical Drug Manufacturers
                       Stock Chart                                 Officers
                                                         Chairman & Chief Executive          Country:
                                                          Dr. Francis E. O'Donnell Jr.       United States

                                                                  President                  Currency:
                                                              Samuel S. Duffey Esq.
                                                                                             U.S. Dollars

                                                         Chief Financial & Accounting
                                                                                      Fiscal Year Ends:
                                                                    Officer
                                                               Garrison J. Hasara     September

                                                                                             Employees
                                                                                             67

                                                                                             Exchanges:
                                                                                             OTC

                                                                                             Share Type:
                                                                                             Common

                                                                                             Market Capitalization:
             Stock Price (8/12/2011): 0.40
                                                  
								
To top